GlassScriptPhysician profile
Carol J Workman
NPI 1366490138
$5,690.40
in general payments reported to CMS, 2019-2025
22 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $1,421 · 2021: $1,670 · 2022: $247 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $1,330.06 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $820.61 | 2019-2021 | |
| Abbvie INC. | $496.08 | 2021-2025 | |
| Amarin Pharma, INC. | $466.97 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $413.67 | 2019-2021 | |
| Amgen INC. | $379.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.06 | 2019-2021 | |
| Mentor Worldwide LLC | $261.20 | 2019-2020 | |
| Becton, Dickinson and Company | $250.17 | 2025 | Phasix Mesh |
| Janssen Pharmaceuticals, INC | $208.67 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $160.50 | 2019 | |
| Novo Nordisk INC | $143.43 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $131.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.21 | 2019 | |
| Allergan, INC. | $66.01 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $64.30 | 2025 | Veozah |
| Davol INC. | $48.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $27.43 | 2021 | |
| Lilly USA, LLC | $12.33 | 2020 | |
| Pfizer INC. | $11.59 | 2019 | |
| Daiichi Sankyo INC. | $11.49 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.